Monoclonal antiidiotypic antibodies related to a murine oncofetal bladder tumor antigen induce specific cell-mediated tumor immunity.

Abstract

Rat

Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.

“…This is in agreement with observations made in other systems, where an immune response to tumor-associated "self' antigens has been induced by using the appropriate approach (6). Therefore, the fact that melanoma patients do not appear to have either a cellular immune response or circulating antibodies to p97 (C.D.E., personal observations) does not exclude the fact that p97 can be immunogenic in man, and it has been observed by using an in vitro sensitization technique that, indeed, human lymphocytes do have the ability to make anti-p97 antibodies (C. Borrebaeck, personal communication).…”

Treatment of Malignancy with Unmodified Antibody

“…In this case, anti idiotype antibodies produced against the in fused antibody would cross-react with host immune cells. Antibodies against antigenspecific receptors on T-ceils have been shown to be capable of either enhancing or depressing the development of an immune response to an antigen [78][79][80]. For example, Nelson et al [81] and Forstrom et al [82] were able to isolate auto-anti-idiotype anti bodies from mice challenged with murine sarcoma, which reacted with cytotoxic Tcells against the tumor but did not react with the tumor itself.…”

Comparison of T suppressor factors from tumour-bearing mice and mice immunized with a monoclonal anti-idiotypic antibody

“…A bladder transtitional cell carcinoma 1660 [15] and a fibrosarcoma 1511 [20] were used in these experiments. Crude tumour antigen extracts were prepared by homogenization of tumour tissue in phosphate-buffered saline and were standardized and tested for specific reactivity as previously described [ 10,14,15].Antibodies. The production and screening of two monoclonal anti-idiotypic antibodies (MAIA) 21D9 and 5.96 has been described previously [15].…”